ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV

The Defense Logistics Agency awarded TEVA PHARMACEUTICALS USA, INC. a delivery order under the base contract SPE2DP-20-D-0002 for the procurement of 27 packages of Adenovirus Type 4 and Type 7 Vaccine (Live), identified by NSN 6505016420106 and NDC 51285-0138-50, with a total contract value of $515,289.60. The award was made on July 14, 2026, and the product must be delivered FOB destination by July 21, 2026, to the Captain James A. Lovell Federal Health Center in Great Lakes, Illinois, with inspection and acceptance performed by the government at the point of delivery. The contractor is required to use the fastest traceable shipping method, prohibiting parcel post, and all packaging must be clearly marked with the designated government address including the point of contact at Fort Detrick, Maryland, along with the traceable freight identifier M/F: W25MWY61940722. Invoicing is mandatory through the Wide Area WorkFlow system in accordance with DFARS 252.232-7003, and payment will be processed by the Defense Finance and Accounting Service in Columbus, Ohio. The solicitation does not specify packaging, preservation, or thermal control standards despite the biological nature of the vaccine, nor does it reference any military standards for labeling, barcoding, or durability. The contracting officer is Melissa Rios Thomas, with no designated COR or COTR identified. The contractor’s CAGE code is 3V8D7, but no socioeconomic certifications were affirmatively selected, and no clause text from FAR or DFARS was included in the documentation. The order is a firm-fixed-price, single-line-item delivery with zero quantity variance, issued under a larger multiple-award vehicle without option periods or additional CLINs.